You can always buy it back at lower prices if it does head lower. Zacks Investment Research reports that Amgen is a step closer to acquiring Micromet, Inc. with the companies announcing the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976. Amgen and Micromet said that the waiting period was terminated on February 14, a few days before the scheduled date of Feb 17. Amgen had announced its intention to acquire biotech company, Micromet, at the time of releasing its fourth quarter results in January 2012. The companies signed a definitive merger agreement under which Amgen will acquire Micromet for $11 per share in cash or approximately $1.16 billion. The deal has been approved by the Boards of both companies and is scheduled to close later this quarter. The tender offer will remain open until midnight at the end of March 1, 2012, unless the offer is extended. With this acquisition, Amgen is looking to expand its oncology portfolio.